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Abstract
Introduction: The objective of this study was to investigate the contemporary incidence of gout, examine
potential risk factors, and evaluate specific gout treatment patterns in the general population.
Methods: Using the health improvement network (THIN) UK primary care database, we estimated the incidence of
gout based on 24,768 newly diagnosed gout patients among a cohort of 1,775,505 individuals aged 20 to 89 years
between 2000 and 2007. We evaluated potential risk factors for incident gout in a nested case-control study with
50,000 controls frequency-matched by age, sex and calendar time. We calculated odds ratios (OR) by means of
unconditional logistic regression adjusting for demographic variables, lifestyle variables, relevant medical conditions
and drug exposures.
Results: The incidence of gout per 1,000 person-years was 2.68 (4.42 in men and 1.32 in women) and increased
with age. Conventional risk factors were significantly and strongly associated with the risk of gout, with multivariate
ORs of 3.00 (95% confidence interval (CI)) for excessive alcohol intake (that is, more than 42 units per week),
2.34 (95% CI 2.22 to 2.47) for obesity (body mass index > = 30 kg/m2), 2.48 (95% CI 2.19 to 2.81) for chronic renal
impairment, and 3.00 (95% CI 2.85 to 3.15) for current diuretic use. For other medical conditions the multivariate
OR were 1.84 (95% CI 1.70 to 2.00) for heart failure, 1.45 (95% CI 1.18 to 1.79) for hypertriglyceridemia and 1.12
(95% CI 1.04 to 1.22) for psoriasis. Use of cyclosporine was associated with an OR of 3.72 (95% CI, 2.17 to 6.40).
Among gout-specific therapies, allopurinol was the most frequently used with a one-year cumulative incidence of
28% in a cohort of incident gout diagnosed from 2000 to 2001. Use of gout-specific treatment has not changed
over recent years except for an increase of colchicine.
Conclusions: The contemporary incidence of gout in UK remains substantial. In this general population cohort,
associations with previously purported risk factors were evident including psoriasis, heart failure,
hypertriglyceridemia, and cyclosporine therapy. Use of gout-specific treatment has remained relatively constant in
recent years except for an increase of colchicine.
Introduction
Gout is a common and excruciatingly painful inflamma-
tory arthritis affecting at least 1% of the population in
Western countries [1,2]. Gout results from the deposi-
tion of urate (monosodium urate monohydrate) crystals
in a joint, leading to an acute inflammatory response, or
deposition in soft tissues, which can form tophi. Hyper-
uricemia is considered the precursor of gout, while alco-
hol intake, obesity, meat and seafood consumption are
among the established life-style-related risk factors [3,4].
Factors reducing renal clearance of uric acid such as use
of diuretics, and comorbid conditions such as hyperten-
sion, and chronic renal impairment are also involved in
the pathogenesis of gout [3]. Pharmacologic interven-
tions remain an important part of gout management
[5,6].
Several studies have suggested an increase in the dis-
ease burden of gout [1,4,7-10]; however, recent data since
the new millennium are lacking so far. The aims of this
study were to estimate the contemporary incidence of
gout in a UK primary care setting, to quantify the magni-
tude of associations with potential risk factors, including
relevant medical conditions and drug exposures, and to
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describe recent treatment trends in incident gout
patients.
Materials and methods
A nested case-control study was conducted within an
assembled cohort in the Health Improvement Network
(THIN) database. THIN contains computerized informa-
tion entered by general practitioners in the UK [11].
Data on about 3,000,000 patients are systematically
recorded and sent anonymously to THIN. THIN collects
and organizes this information in order for it to be used
for research projects. The computerized information
includes demographics, details from general practi-
tioners’ (GPs) visits, diagnoses from specialists’ referrals
and hospital admissions, results of laboratory tests and a
free text section (information available on request). Pre-
scriptions issued by general practitioners are directly
generated from the computer. An additional require-
ment for participating practices is recording of the
indication for new courses of therapy. The Read classifi-
cation is used to code specific diagnoses, and a drug dic-
tionary based on data from the Multilex classification is
used to code drugs [12,13]. The study was approved by
a UK Multicentre Research Ethics Committee.
The study population included all individuals aged
between 20 to 89 years with a registration status of per-
manent or died in THIN between January 2000 and
December 2007. They were required to have at least
two years of enrolment with the GP, and at least one
GP visit and one prescription in the two years before
entering the source population (start date). This was
done to ensure a minimum complete source of informa-
tion equal to or greater than this time interval prior to
entering the study cohort. Individuals with cancer before
the start date were excluded. For the ascertainment of
incident gout patients, we also excluded all individuals
with a gout diagnosis before the start date (considered
as prevalent gout) from the study population. All indivi-
duals contributed person-time on their respective start
date until the earliest of one of the following criteria,
whichever came first: code suggesting gout, death,
31 December 2007 or 90th birthday. Our final study
population consisted of 1,775,505 individuals followed
up an average of 5.2 years.
Ascertainment of gout patients
The initial ascertainment of gout patients was per-
formed with an automatic computer search. We identi-
fied all individuals with a first-ever diagnosis of gout
recorded in the database during the study period. Sub-
jects with any prescription of specific gout-treatment
(allopurinol, colchicine and uricosuric drugs) before the
start date were identified and considered as prevalent
gout patients. Finally, we ascertained 24,768 newly
diagnosed gout patients (incident gout). The date of
gout diagnosis (index date) was defined as the earliest
date of first diagnosis of gout or first specific gout-
treatment (allopurinol, colchicine and uricosuric drugs)
among individuals with a diagnosis of gout. NSAIDs as
well as steroids were not included in our case definition
to have little specificity to be a treatment for gout and
would, therefore, introduce substantial gout misclassifi-
cation [1]. All incident gout patients were used as cases
in the nested case-control analysis.
To evaluate the robustness of gout ascertainment, we
performed a sensitivity analysis restricting gout cases to
those receiving anti-gout treatment (N = 19,749). To this
end, we used the following operational definition: we
identified within 90 days after the first-ever diagnosis of
gout (index date) any anti-gout treatment (colchicine,
probenecid and uricosuric drugs) and/or a prescription of
NSAIDs on the same index date. A similar case definition
of gout has been shown to have a validity of 90% in the
General Practice Research Database (GPRD) [14,15].
Selection of controls
We randomly selected 50,000 controls using density
sampling. This was done by generating at random a
date encompassed within the study period for each of
the members of the study population. If the random
date for a study member was included in his/her eligible
person-time (follow-up period), we marked that person-
day as an eligible control. The same exclusion criteria
were applied to controls as to cases. Controls were fre-
quency-matched to cases by age within one year, sex
and calendar year (year of newly diagnosed gout). The
random date for controls was used as an index date in
the nested case-control analysis.
Exposure assessment
We collected from the database all the information any
time prior to the index date for traditional life style fac-
tors: smoking, alcohol intake (units per week), personal
characteristics such as body mass index (BMI) in kg/m2,
as well as comorbidities such as ischemic heart diseases,
hypertension, hyperlipidemia, chronic renal impairment
and other disorders. In addition, the number of GP visits,
referrals, and hospitalizations were collected in the year
prior to index date. We classified exposure of drugs into
four mutually exclusive time windows: current use (recent
prescription lasted until index date or ended in the
30 days prior); recent (finished between 31 and 365 days),
past (finished more than 365 days), and never use (no
recorded use at any time prior to index date). Duration
of treatment was calculated among current users of drugs
and was computed summing the time of consecutive pre-
scriptions (allowing for a free interval gap no greater
than 60 days, complete adherence).
Cea Soriano et al. Arthritis Research & Therapy 2011, 13:R39
http://arthritis-research.com/content/13/2/R39
Page 2 of 9
Statistical analysis
Incidence rates of gout over the whole study period as
well as age- and sex-specific ones were estimated and
95% confidence intervals were calculated. We also com-
puted incidence at the beginning (2000 to 2001) and
end (2006 to 2007) of the study period to analyze poten-
tial secular trends.
A nested case-control analysis was performed to esti-
mate the odds ratios (OR) and 95% confidence intervals
(CI) of gout associated with traditional life-style factors,
relevant medical conditions and drug exposures by
means of unconditional logistic regression. The multi-
variable model included the frequency-matched vari-
ables, as well as the number of general practitioner (GP)
visits, and other established risk factors such as alcohol
consumption, body mass index (BMI), ischemic heart
disease (IHD), hypertension, hyperlipidemia, diabetes,
chronic renal impairment, and diuretic use.
We analyzed gout treatment patterns according to
time since the first appearance of a gout diagnosis
among gout patients. We examined the following drug
treatments separately: allopurinol, colchicine and urico-
suric drugs (which included probenecid and sulfinpyra-
zone). We estimated the cumulative incidence of the
specific gout treatment (defined as receiving at least one
prescription) in our incident gout population. We did
not include NSAIDs or steroids as they have multiple
other indications and are less specifically indicated for
gout. For our treatment pattern analysis, we restricted
our cohort of incident gout to patients diagnosed in
2000 and 2001 to ensure the longest possible length of
disease duration. In this inception cohort, we studied
treatment patterns over five time intervals: at one year,
three years, five years, seven years and nine years after
the first appearance of a gout diagnosis. We also com-
pared the cumulative incidence of anti-gout treatment
at one year after gout onset between patients who devel-
oped incident gout in 2000 to 2001 and those in 2006 to
2007. All statistical procedures were performed with the
STATA package version 11.0 (StataCorp LP, College
Station, TX, USA).
Results
We identified 24,768 newly diagnosed gout patients cor-
responding to a crude incidence rate of 2.68 (95% CI
2.65 to 2.72) per 1,000 person-years among individuals
aged 20 years or older. The incidence of gout was 4.42
(95% CI 4.36 to 4.48) in men and 1.32 (95% CI 1.29 to
1.35) in women per 1,000 person-years. The incidence
of gout increased with increasing age (Figure 1). The
corresponding male/female ratio was 3.4. When we
restricted our population to individuals aged 70 years
and above the corresponding male/female ratio was 2.3.
Mean age at first diagnosis of gout was 60.1 years (95%
CI 59.9 to 60.4) among men and 67.7 years (95% CI
67.3 to 68.0) among women, respectively.
Incidence rate was 2.67 (95% CI 2.59 to 2.75) in 2000
to 2001 and 2.52 (95% CI 2.46 to 2.57) in 2006 to 2007.
Sex and age specific incidence rate remained relatively
constant between both time periods (Figure 2).
Table 1 shows the results of the nested case-control
analysis. Among the traditional risk factors for gout, obe-
sity, alcohol consumption, diuretics use, and hypertension
were independently associated with the risk of incident
gout. A dose response was observed according to alcohol
consumption and BMI. Consumers between 25 and
42 units per week presented an OR of 2.45 (95% CI 2.27
to 2.63), and 3.00 (95% CI 2.66 to 3.38) among consu-
mers greater than 42 units per week compared with
abstainers. Individuals with a BMI between 25 and 29 kg/
m2 had an OR of 1.62 (95% CI 1.55 to 1.70) and those
with BMI of 30 kg/m2 or greater an OR of 2.34 (95% CI
2.22 to 2.47) compared to those with a BMI in the nor-
mal range (20 to 24 kg/m2). A history of chronic renal
impairment showed an OR of 2.48 (95% CI 2.19 to 2.81)
and hypertension an OR of 1.18 (95% CI 1.13 to 1.23).
Among suspected medical conditions, prior history of
congestive heart failure was strongly associated with an
increased risk of incident gout, whereas ischemic heart
disease was modestly associated with an increased risk.
While hypertriglyceridemia was associated with a clear
increased risk of gout (multivariate OR, 1.45 (95% CI,
1.18 to 1.79), other dyslipidemias and hypercholesterole-
mia presented an OR of 1.21 (95% CI, 1.12 to 1.31), and
1.08 (95% CI, 1.02 to 1.14), respectively. No increased
risk was found among patients with prior nephrolithia-
sis, whereas psoriasis was associated with a slightly
increased risk of gout (multivariate OR, 1.12; 95% CI,
1.04 to 1.22). The only medical condition associated
with a reduced risk of gout was diabetes with an OR of
0.66 (95% CI 0.62 to 0.71) (Table 1).
Both current and recent users of diuretics showed a
significantly higher risk of gout. This increased risk
returned to the baseline one year after stopping diuretics
(Table 2). Additional analyses showed that after adjust-
ing for heart failure, the increased risk among current
users of diuretics was slightly reduced, but remained
strong (OR (2.76: 95% CI 2.62 to 2.90)). The risk of
gout was 2.20 (95% CI 2.05 to 2.38) among diuretic cur-
rent users with less than one-year duration. The esti-
mates were 2.85 (95% CI 2.62 to 3.11) and 3.42 (95% CI
3.23 to 3.62) among users on diuretics treatment
between one to two years and longer than two years,
respectively (P for duration response <0.001).
Among suspected medications, current users of low
dose aspirin presented a multivariate OR of 0.95 (95%
CI 0.90 to 1.00). When we analyzed the association with
aspirin < = 75 mg daily (mini-dose aspirin), which was
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the dose used in 80% of aspirin users, the estimate of
risk remained the same (0.95, 95% CI 0.90 to 1.00).
NSAID current users showed a multivariate OR of 3.07
(95% CI 2.90 to 3.24) (Table 2).
When we also analyzed the association according to
the time when NSAID treatment was started, it was
apparent that the risk was mainly concentrated among
current users within the first month with an OR of 7.01
(95% CI 6.46 to 7.61) while those with a use of one year
or greater presented an OR of 1.11 (95% CI 1.01 to
1.23), suggesting reverse causality (that is, potential
NSAID: treatment for early gout symptoms), among
users in the first month of use (data not shown).
Use of cyclosporine was rare, but was associated with
an OR of 3.72 (95% CI 2.17 to 6.40). The risk was rather
constant over treatment duration with an OR of 4.16
(95% CI 2.21 to 7.83) among users of one year or
longer. Azathioprine, another post-organ transplantation
drug, showed an OR of 0.93 (95% CI 0.64 to 1.34). We
found women on hormone replacement therapy (HRT)
to have an OR of 0.86 (95% CI 0.74 to 1.01).
Next, we analyzed gout treatment patterns during
recent years. Cumulative incidence of specific gout treat-
ment at different time intervals among the subcohort of
newly diagnosed gout patients in 2000 to 2001 (N =
4,349) is presented in Figure 3. One year after first-ever
Figure 1 Sex and age specific incidence rate of gout 2000 to 2007 in the THIN database. Incidence rates per 1,000 person-years: overall
2.68 (95% CI 2.65 to 2.72), men 4.42 (95% CI 4.36 to 4.48), women 1.32 (95% CI 1.29 to 1.35).
Figure 2 Sex and age specific incidence rate of gout in 2000/2001 and 2006/2007. 2000 to 2001: Incidence rates per 1,000 person-years:
overall 2.67 (95% CI 2.59 to 2.75), men 4.48 (95% CI 4.33 to 4.64), women 1.28 (95% CI 1.21 to 1.35). 2006 to 2007: Incidence rates per 1,000
person-years: overall 2.52 (95% CI 2.46 to 2.57), men 4.01 (95% CI 3.91 to 4.12), women 1.25 (95% CI 1.20 to 1.30).
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gout diagnosis, use of allopurinol presented the highest
cumulative incidence with 28.2% (95% CI, 26.9 to 29.6)
followed by colchicine with 13.8% (95% CI 12.8 to 14.8).
Use of uricosuric agents was very low with a cumulative
incidence of 0.2% (95% CI, 0.1 to 0.4). At nine years, the
cumulative incidence of the various gout treatments was
about twice as high compared to the use during the first
year after gout diagnosis. This pattern was consistent
among the three anti-gout treatments.
When we analyzed the use during the first year in a
cohort of gout diagnosed in 2006 to 2007 (N = 7,089),
the cumulative incidence was 24.3% (95% CI 23.3 to
25.3) for allopurinol and 0.2% (95% CI 0.1 to 0.3) for
uricosuric drugs. Only colchicine showed a higher use
Table 1 Relative risk (OR) of gout according to lifestyle factors and comorbidities
Characteristics Controls N = 50,000 N (%) Gout cases N = 24,768 N (%) Multivariate OR (95% CI)*
Sex
Male 36,953 (73.91) 17,946 (72.46) -
Female 13,047 (26.09) 6,822 (27.54) -
Age
20 to 49 years 10,211 (20,42) 5,290 (21.36) -
50 to 59 years 10,111 (20.22) 4,873 (19.67) -
60 to 69 years 11,930 (23.86) 5,753 (23.23) -
70 to 79 years 11,896 (23.79) 5,858 (23.65) -
80 to 89 years 5,852 (11.70) 2,994 (12.09) -
Alcohol (units per week)‡
Non-use 16,396 (32.79) 7,628 (30.80) 1 (ref)
1 to 9 u/w 13,362 (26.72) 5,960 (24.06) 1.06 (1.01 to 1.11)
10 to 24 u/w 8,150 (16.30) 5,074 (20.49) 1.56 (1.49 to 1.65)
25 to 42 u/w 2,152 (4.30) 2,053 (8.29) 2.45 (2.27 to 2.63)
more than 42 u/w 633 (1.27) 739 (2.98) 3.00 (2.66 to 3.38)
unknown 9,307 (18.61) 3,314 (13.38) 1.15 (1.08 to 1.23)
BMI (kg/m2)
15 to 19 1,588 (3.18) 315 (1.27) 0.66 (0.58 to 0.76)
20 to 24 13,899 (27.80) 4,225 (17.06) 1 (ref)
25 to 29 16,623 (33.25) 9,169 (37.02) 1.62 (1.55 to 1.70)
> = 30 7,412 (14.82) 7,176 (28.97) 2.34 (2.22 to 2.47)
unknown 10,478 (20.96) 3,883 (15.68) 1.48 (1.39 to 1.57)
Number of GP visits
0 to 4 visits 22,700 (45.40) 6,785 (27.39) 1 (ref)
5 to 9 visits 13,201 (26.40) 6,692 (27.02) 1.38 (1.32 to 1.44)
10 to 19 visits 10,422 (20.84) 7,400 (29.88) 1.66 (1.58 to 1.74)
> = 20 visits 3,677 (7.35) 3,891 (15.71) 2.13 (1.99 to 2.27)
Chronic renal failure 467 (0.93) 947 (3.82) 2.48 (2.19 to 2.81)
Hypertension 16,280 (32.56) 12,858 (51.91) 1.18 (1.13 to 1.23)
Heart failure 1,422 (2.84) 2,142 (8.65) 1.84 (1.70 to 2.00)
Ischemic heart disease 6,716 (13.43) 4,923 (19.88) 1.19 (1.14 to 1.25)
Hyperlipidemia
Hypercholesterolemia† 4,188 (8.38) 3,124 (12.61) 1.08 (1.02 to 1.14)
Hypertrygliceridemia† 218 (0.44) 216 (0.87) 1.45 (1.18 to 1.79)
Other dyslipidemia† 1,849 (3.70) 1,699 (6.86) 1.21 (1.12 to 1.31)
Diabetes 3,885 (7.77) 2,404 (9.71) 0.66 (0.62 to 0.71)
Nephrolithiasis 776 (1.55) 446 (1.80) 1.03 (0.91 to 1.18)
Psoriasis 1,894 (3.79) 1,173(4.74) 1.12 (1.04 to 1.22)
*Odds ratio (OR) adjusted for sex, age, calendar year, number of GP visits, BMI, alcohol consumption, IHD, hypertension, hyperlipidemia, diabetes, chronic renal
failure and use of diuretics.
†Note: The estimate of each variable was calculated by removing hyperlipidemia from the model.
‡1 unit = 10 ml of pure ethanol (eight grams of alcohol).
Cea Soriano et al. Arthritis Research & Therapy 2011, 13:R39
http://arthritis-research.com/content/13/2/R39
Page 5 of 9
in 2006 to 2007 with a cumulative incidence of 19.7%
(95% CI 18.8 to 20.7) compared to 13.8 (95% CI 12.8 to
14.8) in 2000 and 2001 (Figure 4).
Discussion
In this large UK primary care population, we found that
the incidence of gout remained stable between 2000 and
2007. Our contemporary data corroborated previously
shown risk factors, including alcohol intake, obesity,
chronic renal impairment, cardiovascular conditions,
and diuretic use. Furthermore, we have examined other
purported medical conditions and medications, about
which we are not aware of any previous large-scale evi-
dence. We found that prior histories of ischemic heart
disease, heart failure, hyperlipidemia, and psoriasis are
independently associated with an increased risk of gout,
whereas diabetes was associated with a lower risk of
gout. Interestingly, among subtypes of hyperlipidemia,
hypertriglyceridemia was associated with an increased
risk, whereas this pattern was much less clear among
patients with hypercholesterolemia. We also found that
among post-transplant drugs cyclosporine was the only
agent associated with increased risk of gout. Finally, the
frequency of anti-gout medication use has remained
Table 2 Relative risk (OR) of gout associated with use of various medications
Co-medication Controls N = 50,000 N (%) Gout Cases N = 24,768 N (%) Multivariate OR (95%CI)*
Diuretics
Never use 36,237 (72.47) 12,206 (49.28) 1(ref)
Current (<31 days) 8,582 (17.16) 9,921 (40.06) 3.00 (2.85 to 3.15)
Recent (31 to 365 days) 1,462 (2.92) 1,050 (4.24) 1.83 (1.67 to 2.01)
Past (>365 days) 3,719 (7.44) 1,591 (6.42) 1.10 (1.02 to 1.18)
Aspirin low-dose
Never use 38,737 (77.47) 16,924 (68.33) 1 (ref)
Current (<31 days) 7,788 (15.58) 5,291 (21.36) 0.95 (0.90 to 1.00)
Recent (31 to 365 days) 1,292 (2.58) 938 (3.79) 1.12 (1.02 to 1.24)
Past (>365 days) 2,183 (4.37) 1,615 (6.52) 1.10 (1.02 to 1.19)
NSAIDs
Never use 20,989 (41.98) 6,735 (27.19) 1 (ref)
Current (<31 days) 4,064 (8.13) 4,791 (19.34) 3.07 (2.90 to 3.24)
Recent (31 to 365 days) 5,616 (11.23) 4,107 (16.58) 2.05 (1.94 to 2.16)
Past (>365 days) 19,331 (38.66) 9,135 (36.88) 1.29 (1.24 to 1.35)
Transplant rejection drugs†
Never use 49,792 (99.58) 24,586 (99.27) 1 (ref)
Current (<31 days) 94 (0.19) 90 (0.36) 1.12 (0.80 to 1.57)
Recent (31 to 365 days) 21 (0.04) 23 (0.09) 1.50 (0.77 to 2.93)
Past (>365 days) 93 (0.19) 69 (0.28) 1.14 (0.81 to 1.60)
Azathioprine
Never use 49,794 (99.59) 24607 (99.35) 1 (ref)
Current (<31 days) 89 (0.18) 65 (0.26) 0.93 (0.64 to 1.34)
Recent (31 to 365 days) 22 (0.04) 20 (0.08) 1.11 (0.56 to 2.22)
Past (>365 days) 95 (0.19) 76 (0.31) 1.21 (0.87 to 1.68)
Cyclosporine
Never use 49,941 (99.88) 24,657 (99.55) 1 (ref)
Current (<31 days) 20 (0.04) 75 (0.30) 3.72 (2.17 to 6.40)
Recent (31 to 365 days) 6 (0.01) 10 (0.04) 1.42 (0.46 to 4.38)
Past (>365 days) 33 (0.07) 26 (0.10) 0.91 (0.52 to 1.61)
Hormonal replacement therapy (HRT) (women only)
Never use 10,436 (79.99) 5,368 (78.69) 1 (ref)
Current (<31 days) 785 (6.02) 345 (5.06) 0.86 (0.74 to 1.01)
Recent (31 to 365 days) 347 (2.66) 192 (2.81) 1.07 (0.87 to 1.32)
Past (>365 days) 1,479 (11.34) 917 (13.44) 1.02 (0.91 to 1.13)
*Odds ratio (OR) adjusted for sex, age, calendar year, number of GP visits, BMI, alcohol consumption, IHD, hypertension, hyperlipidemia, diabetes, chronic renal
failure and use of diuretics.
† Transplant rejection drugs include: azathioprine, mycophenolate mofetil, mycophenolic acid, sirolimus, tacrolimus.
NSAIDs, nonsteroidal anti-inflammatory drugs.
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relatively unchanged in recent years except for an
increase of colchicine.
Our estimate of incidence rate increased from 0.4 per
1,000 person-years in women of 40 to 49 years, to 3.6 in
women of 70 to 79 years. Our results are in line with a
prior study [16] that reported an incidence rate of gout
of 0.6 per 1,000 person-years in women <45 years and
2.5 in women over the age of 75. When we restricted
our cohort to individuals aged 40 years and older, our
estimate of incidence (3.5 per 1,000 person-years) was
in close agreement with a recent UK study, which esti-
mated an incidence rate of gout 3.2 per 1,000 person-
years [9]. Although the mean age of first diagnosis was
60.1 years in males and 67.7 years in females, almost
40% of all incident gout cases were younger than
60 years, indicating that many middle-aged subjects
were affected. Male preponderance was more marked in
individuals less than 60 years. The different age depen-
dence between males and females in the incidence of
gout could in part be due to hormonal status. The uri-
cosuric effects of estrogens could lead to a protective
effect on the risk of gout in premenopausal women
[17-20]. We also observed that women on exogenous
hormonal treatment had 14% less risk of developing
gout, and the reduced risk disappeared after stopping
HRT, a finding previously reported in a large prospec-
tive cohort study of female nurses [16].
Our findings confirm the relationship between tradi-
tional risk factors with well-known effects on increasing
uric acid levels and subsequently the risk of gout
[21,22]. Our cohort data showed a clear dose-response
relation between alcohol consumption and the risk of
gout, similar to previous studies [23]. Similarly, our
results showed a continuous increased risk of gout with
increasing BMI as well as a protective effect in indivi-
duals with a BMI under 20 kg/m2. Bidirectional associa-
tions between weight loss and the prevention of gout
and weight gain and the development of gout were
reported in the Health Professionals Follow up Study
[10]. Chronic renal impairment more than doubled the
risk of developing incident gout, which is likely due to
decreased urate excretion resulting in uric acid accumu-
lation [4,24]. Beyond the effect of this and other medical
conditions, the use of diuretics, in particular among
users of one year and longer than one year, was asso-
ciated with a three-fold increased risk of gout.
We also evaluated other suspected risk factors lacking
in large-scale epidemiologic data, such as lipid abnorm-
alities, ischemic heart disease, congestive heart failure,
psoriasis, and various medications. While all subtypes of
hyperlipidemia showed independent associations with
the risk of incident gout [25], the association with
hypertriglyceridemia was most prominent. Elevated tri-
glyceride level is a cardinal feature of insulin resistance,
which is closely associated with elevated serum uric acid
levels. Individuals with diabetes showed a reduced risk
Figure 3 Cumulative incidence of gout treatment over gout disease duration.
Figure 4 One-year cumulative incidence of gout treatment in
2000 to 2001 and 2006 to 2007.
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of gout. Some studies have reported lower uric acid
levels among diabetes patients [26,27]. We also found
that prior history of congestive heart failure and
ischemic heart disease was independently associated
with an increased risk of gout. Associated relative tissue
hypoxia, increased lactate levels, or accelerated adeno-
sine triphosphate (ATP) consumption could increase the
risk of hyperuricemia and gout in patients with these
conditions [28,29]. Recently, a case-control study with
only 60 individuals with gout and 6 with heart failure
(HF) reported an increased risk of gout among patients
with HF [30,31]. Interestingly, this study also reported
that diuretic use did not increase the risk of gout after
adjusting for HF and other cardiovascular conditions, as
these factors are closely associated with each other
[30,31]. Our study, with substantially larger study sam-
ples (n with gout = 24,768 and n with HF = 3,564), was
able to detect independent associations with each of
these two factors. Psoriasis is a disorder associated with
increased cell turnover leading to increased uric acid
production [3] and our cohort confirmed a small but
significantly increased risk of incident gout. Finally, the
absence of an association between history of nephro-
lithiasis and risk of gout was consistent with the result
reported by Kramer et al. [32,33].
Current use of low-dose aspirin was more common
among gout patients than controls. However, after adjust-
ing for other covariates, including history of ischemic
heart disease, low-dose aspirin was not associated with an
increased risk of gout. This suggests that the independent
pathogenetic role of low-dose aspirin use, if any, may be
minor on the risk of incident gout. Our study confirmed
an increased risk of gout among users of cyclosporine (an
immunosuppressant drug indicated in organ transplant,
psoriasis, rheumatoid arthritis, and nephrotic syndrome),
whereas there was no association with use of azathioprine
or other medications indicated after organ transplant
[4,34,35]. The apparent association between NSAID use
and risk of gout was restricted to patients recently started
before the recorded diagnosis of gout. This observation
suggests substantial confounding by indication, where use
within the first month could be a proxy (treatment) for
early manifestations of gout, although a true association
cannot be ruled out entirely.
In terms of anti-gout medication use during recent
years, we found that allopurinol use had the highest fre-
quency, followed by colchicine, whereas a small propor-
tion of gout patients were taking uricosuric drugs.
Treatment patterns did not change in recent years, with
only colchicine showing an increase. While allopurinol use
seems to be in line with a previous study based on the
GPRD between 1990 and 1999, colchicine use appears to
have increased since the 1990s, when the authors reported
an annual frequency of colchicine use of only 1 to 3% [1].
In addition, it should be noted that the greater proportion
of colchicine use could also be explained in part by the
fact that our study is based exclusively on individuals
newly-diagnosed with a first gout attack, when colchicine
prophylaxis is used more often [6].
The strengths and limitations of our study deserve
comment. Our study was performed with a large popu-
lation-based database which contains computerized
information entered by primary care physicians that per-
mits the extrapolation of results to the general popula-
tion. Also, under our design of incidence density
sampling, the OR is an unbiased estimator of the inci-
dence rate ratio. Some level of misclassification is una-
voidable when working with computerized databases;
however, the impact of non-differential misclassification
would have most likely biased our estimates of effect
toward the null and would not explain the strong asso-
ciations and dose-response relationships observed in our
study. Furthermore, in a secondary analysis when we
restricted gout cases to those with GPs’ diagnoses of
gout combined with anti-gout medication use, our
results remained similar (data not shown).
Conclusions
In conclusion, our findings suggest that the contempor-
ary disease burden of gout remains substantial in the
UK. Previously identified risk factors still pose consider-
able relative risk in this cohort, including alcohol intake,
obesity, chronic renal impairment, several cardiovascular
conditions, and diuretic use. In addition, we found inde-
pendent associations with prior history of ischemic
heart disease, hyperlipidemia, heart failure and psoriasis,
and with the use of cyclosporine. These data support
the notion that appropriate pharmacologic management
and control of lifestyle factors such as maintenance of a
healthy BMI, alcohol consumption, and comorbidities,
including hypertension and chronic renal failure, would
reduce the burden of this common and excruciatingly
painful inflammatory arthritis.
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